Neoadjuvant therapy for pancreatic cancer
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …
surgical resection of the primary tumour and systemic chemotherapy, which provides …
Pancreatic cancer: a review of risk factors, diagnosis, and treatment
ZY Zhao, W Liu - Technology in cancer research & treatment, 2020 - journals.sagepub.com
This review aims to summarize the latest knowledge on factors, diagnosis, and treatment of
pancreatic cancer, and aims to promote further research on this under-studied malignant …
pancreatic cancer, and aims to promote further research on this under-studied malignant …
[HTML][HTML] Proteogenomic characterization of pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …
survival. Toward understanding the underlying molecular alterations that drive PDAC …
Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system
S Schuth, S Le Blanc, TG Krieger, J Jabs… - Journal of Experimental …, 2022 - Springer
Abstract Background Cancer-associated fibroblasts (CAFs) are considered to play a
fundamental role in pancreatic ductal adenocarcinoma (PDAC) progression and …
fundamental role in pancreatic ductal adenocarcinoma (PDAC) progression and …
The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic …
Pancreatic ductal adenocarcinoma (PDAC) is one of the lethal malignancies with the lowest
median and overall survival rate among all human malignancies. The major problems with …
median and overall survival rate among all human malignancies. The major problems with …
SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine
ZW Wang, JJ Pan, JF Hu, JQ Zhang, L Huang, Y Huang… - Cell reports, 2022 - cell.com
Serine/arginine-rich splicing factor 3 (SRSF3) regulates mRNA alternative splicing of more
than 90% of protein-coding genes, providing an essential source for biological versatility …
than 90% of protein-coding genes, providing an essential source for biological versatility …
Target c-Myc to treat pancreatic cancer
M Ala - Cancer biology & therapy, 2022 - Taylor & Francis
ABSTRACT C-Myc overexpression is a common finding in pancreatic cancer and predicts
the aggressive behavior of cancer cells. It binds to the promoter of different genes, thereby …
the aggressive behavior of cancer cells. It binds to the promoter of different genes, thereby …
CircFOXK2 promotes growth and metastasis of pancreatic ductal adenocarcinoma by complexing with RNA-binding proteins and sponging MiR-942
The detailed biological functions of circular RNA (circRNA) are largely unexplored. Using
circRNA sequencing, we identified 169 differentially expressed circRNA in pancreatic ductal …
circRNA sequencing, we identified 169 differentially expressed circRNA in pancreatic ductal …
ALKBH5-mediated m6A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling
Y He, HQ Yue, Y Cheng, Z Ding, Z Xu, C Lv… - Cell death & …, 2021 - nature.com
Long noncoding RNAs (lncRNAs) are regarded as crucial regulators in tumor progression.
Potassium two pore domain channel subfamily K member 15 and WISP2 antisense RNA 1 …
Potassium two pore domain channel subfamily K member 15 and WISP2 antisense RNA 1 …
Ferroptosis: At the crossroad of gemcitabine resistance and tumorigenesis in pancreatic cancer
J Yang, J Xu, B Zhang, Z Tan, Q Meng, J Hua… - International Journal of …, 2021 - mdpi.com
The overall five-year survival rate of pancreatic cancer has hardly changed in the past few
decades (less than 10%) because of resistance to all known therapies, including …
decades (less than 10%) because of resistance to all known therapies, including …